NELARABINE

NELARABINE
Arranon
Classifications: antineoplastic; pyrimidine, antimetabolite;
Therapeutic: antineoplastic
; antimetabolite
Prototype: 5-Fluorouracil
Pregnancy Category: D

Availability

5 mg/mL solution

Action

Nelarabine inhibits DNA synthesis in lymphoblastic T-cells of acute leukemia and lymphoma.

Therapeutic Effect

The incorporation of a nelarabine metabolite in the leukemic blast cells halts DNA synthesis and causes cell death.

Uses

Treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

Contraindications

Severe bone marrow suppression; older adults; pregnancy (category D); lactation.

Cautious Use

Severe renal impairment, renal failure; hepatic impairment.

Route & Dosage

Adult T-Cell Leukemia/Lymphoma
Adult: IV 1500 mg/m2 over 2 h on days 1, 3, and 5, repeated every 21 d
Child: IV 650 mg/m2 over 1 h for 5 d, repeated every 21 d

Administration

  • Standard IV hydration, urine alkalinization, and prophylaxis with allopurinol are advised to manage hyperuricemia in those at risk for tumor lysis syndrome.
  • Use gloves and protective clothing to prevent skin contact.
Intravenous

PREPARE: IV Infusion: Do not dilute. Transfer the required dose to a PVC or glass container for infusion.  

ADMINISTER: IV Infusion for Adult: Give over 2 h.  IV Infusion for Child: Give over 1 h. ??Discontinue IV and notify physician for neurologic adverse events of NCI Common Toxicity Criteria grade 2 or greater. 

  • Store vials at 15°–30° C (59°–86° F). Nelarabine is stable in PVC bags or glass infusion containers for 8 h up to 30° C.

Adverse Effects (≥1%)

Body as a Whole: Abnormal gait, fatigue, pyrexia, rigors. CNS: Asthenia, ataxia, dizziness, headache, hypoesthesia, neuropathy, paresthesia, somnolence, tremor. CV: Chest pain, edema, hypotension, petechiae, sinus tachycardia. GI: Abdominal pain, constipation, diarrhea, nausea, vomiting, stomatitis. Hematologic/Lymphatic: Anemia, neutropenia, thrombocytopenia, increased risk of infection. Hepatic: AST levels increased. Metabolic: Anorexia, dehydration, hyperglycemia. Musculoskeletal: Arthralgia, back pain, muscular weakness, myalgia, pain in extremities. Respiratory: Cough, dyspnea, pleural effusion, epistaxis, wheezing.

Pharmacokinetics

Distribution: Extensive. Metabolism: Bioactivation to ara-GTP, oxidized to uric acid. Elimination: Renal. Half-Life: 3 h (active metabolite).

Nursing Implications

Assessment & Drug Effects

  • Monitor for and report immediately S&S of adverse CNS effects, including altered mental status (e.g., confusion, severe somnolence), seizures, and peripheral neuropathy (e.g., numbness, paresthesias, motor weakness, ataxia, paralysis). Note: Previous or concurrent treatment with intrathecal chemotherapy or previous craniospinal irradiation may increase risk of CNS toxicity.
  • Monitor for S&S of bleeding, especially with platelet counts <50,000/mm3.
  • Lab tests: Baseline and periodic CBC with differential and platelet count; periodic serum electrolytes, serum uric acid, LFTs, and renal function test.
  • Monitor diabetics for loss of glycemic control.
  • Note: Previous or concurrent treatment with intrathecal chemotherapy or previous craniospinal irradiation may increase risk of CNS toxicity.

Patient & Family Education

  • Do not drive or engage in potentially hazardous activities until response to drug is known.
  • Report any of the following to a health care provider: seizures; tingling or numbness in hands and feet; problems with fine motor coordination; unsteady gait and increased weakness with ambulating; fever or other signs of infections; black tarry stools, blood tinged urine, or other signs of bleeding.
  • Use effective contraceptive measures to avoid pregnancy while taking this drug.

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

(33)
This site is intended for general information only. The information provided on this site does not constitute medical advice and should not be relied upon. You should not act or refrain from acting on any legal or medical matter based on the content of this site.
© 2006-2025 medpill.info Last Updated On: 04/08/2025 (0)
×
Wait 20 seconds...!!!